4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow Themis Bioscience GmbH: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chikungunya Vaccine (V184) Study in Previously Exposed Adults (V184-006) V184, Placebo - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 41 | 2019-07-16 | 2022-09-08 |
| Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005) MV-CHIK lyophilised formulation, low dose, MV-CHIK liquid frozen formulation, low dose, MV-CHIK SPS® formulation, low dose - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 60 | 2018-08-22 | 2021-10-22 |
| Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area MV-CHIK, MMR-vaccine - Chikungunya | Phase 2 | Completed | Themis Bioscience GmbH | 34 | 2017-08-09 | 2021-07-19 |
| Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine MV-CHIK low dose, MV-CHIK high dose, Priorix® - Chikungunya Virus Infection | Phase 2 | Completed | Themis Bioscience GmbH | 263 | 2016-08-17 | 2021-10-29 |
Chikungunya Fever (4) · Communicable Diseases (1)
Measles-Mumps-Rubella Vaccine (2) · Dosage Forms (1) · Sodium Chloride (1)
Puerto Rico (2) · Austria (1) · Germany (1) · United Kingdom (1)
PMID 25739878, PMID 30409443, PMID 34582377
2015 (1), 2018 (1)